Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03823404Phase 2Completed

GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

Role: lead

NCT04920903Phase 1Completed

A Single and Multiple Ascending Dose Study of COR588

Role: lead

NCT03418688Phase 1Completed

A Multiple Ascending Dose Study of COR388

Role: lead

NCT03331900Phase 1Completed

Study of COR388 HCl in Healthy Subjects

Role: lead

All 4 trials loaded